CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced on January 4, 2018 the pricing of a public offering of 5 million of its shares at an offering price of $22.75 per share, before underwriting discounts.
In addition, an option to purchase up to an additional 750,000 shares that has been by CRISPR Therapeutics to the underwriters was exercised in full.
The gross proceeds from the offering (including the 750,000 option shares), before deducting the underwriter discounts and commissions and other offering expenses, are estimated to be ap-proximately $130.8m.
Goldman Sachs, Piper Jaffray & Co and Barclays Capital are acting as joint book-running managers; Guggenheim Securities is acting as co-manager for the offering.
Goodwin Procter advises CRISPR Therapeutics on US law, Vischer on Swiss law. The team at Vischer is led by Matthias Staehelin (partner) with Angelo Imperiale (associate), both corporate.